Processing

Please wait...

Settings

Settings

Goto Application

1. WO2012068454 - NRF2 DEFICIENCY INFLUENCES SUSCEPTIBILITY TO STEROID RESISTANCE VIA HDAC2 REDUCTION

Publication Number WO/2012/068454
Publication Date 24.05.2012
International Application No. PCT/US2011/061380
International Filing Date 18.11.2011
IPC
A61K 31/385 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
38having sulfur as a ring hetero atom
385having two or more sulfur atoms in the same ring
A61K 31/38 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
38having sulfur as a ring hetero atom
A61K 31/573 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopentahydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
57substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
573substituted in position 21, e.g. cortisone, dexamethasone, prednisone
A61K 31/56 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopentahydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
A61P 29/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
29Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (NSAIDs)
CPC
A61K 31/05
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
05Phenols
A61K 31/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
12Ketones
A61K 31/216
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
21Esters, e.g. nitroglycerine, selenocyanates
215of carboxylic acids
216of acids having aromatic rings, e.g. benactizyne, clofibrate
A61K 31/26
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
21Esters, e.g. nitroglycerine, selenocyanates
26Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
A61K 31/277
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
275Nitriles; Isonitriles
277having a ring, e.g. verapamil
A61K 31/352
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
35having six-membered rings with one oxygen as the only ring hetero atom
352condensed with carbocyclic rings, e.g. cannabinols, methantheline
Applicants
  • UNIVERSITY OF ROCHESTER [US]/[US] (AllExceptUS)
  • RAHMAN, Ifran [GB]/[US] (UsOnly)
Inventors
  • RAHMAN, Ifran
Agents
  • STEFFE, Eric, K.
Priority Data
61/415,59119.11.2010US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) NRF2 DEFICIENCY INFLUENCES SUSCEPTIBILITY TO STEROID RESISTANCE VIA HDAC2 REDUCTION
(FR) INFLUENCE D'UNE DÉFICIENCE EN NRF2 SUR LA SENSIBILITÉ À LA RÉSISTANCE AUX STÉROÏDES PAR LE BIAIS D'UNE DIMINUTION DE LA CONCENTRATION EN HDAC2
Abstract
(EN)
Methods for the treatment or prevention of diseases which are caused by the decreased concentrations of histone deacetylase 2 (HDAC2) in cells are described. The diseases which may be treated by the methods of the invention include chronic obstructive pulmonary disease (COPD) and asthma, including steroid resistant COPD and asthma. The invention provides methods for treating or preventing of diseases caused by the degradation of HDAC2 by providing to the subject in need of treatment or prevention a molecular compound capable of preventing the degradation of HDAC2. Such molecular compounds include Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) activators. Methods are further provided for the treatment and prevention of COPD and asthma by providing to a subject in need of such treatment and prevention a nucleic acid which causes expression of HDAC2 in lung cells and/or a nucleic acid which causes expression of Nrf2 in lung cells.
(FR)
La présente invention concerne des procédés de traitement ou de prévention de maladies qui sont provoquées par une baisse des concentrations d'histone désacétylase 2 (HDAC2) dans les cellules. Les maladies qui peuvent être traitées par les procédés de l'invention comprennent des maladies pulmonaires obstructives chroniques (COPD) et l'asthme, comprenant des COPD résistantes aux stéroïdes et l'asthme. L'invention concerne ainsi des procédés de traitement ou de prévention de maladies provoquées par la dégradation de la HDAC2 en administrant au sujet ayant besoin d'un traitement ou d'une prévention un composé moléculaire capable de prévenir la dégradation de la HDAC2. De tels composés moléculaires comprennent des activateurs de facteurs nucléaires de type 2 (dérivés d'érythroïdes 2). L'invention concerne en outre des procédés de traitement et de prévention de COPD et de l'asthme en administrant au sujet ayant besoin d'un tel traitement ou prévention un acide nucléique entraînant l'expression de la HDAC2 dans les cellules des poumons et/ou un acide nucléique entraînant l'expression du Nrf2 dans les cellules des poumons.
Also published as
Latest bibliographic data on file with the International Bureau